April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Protective effects of Growth Hormone Releasing Hormone (GHRH) agonism in the diabetic retina
Author Affiliations & Notes
  • Sean Shaw
    Ophthalmology, Georgia Regents University, Augusta, GA
  • Sagar Yatin Patel
    Ophthalmology, Georgia Regents University, Augusta, GA
  • Folami Lamoke
    Ophthalmology, Georgia Regents University, Augusta, GA
  • Jianghe Yuan
    Ophthalmology, Georgia Regents University, Augusta, GA
  • Alan Saul
    Ophthalmology, Georgia Regents University, Augusta, GA
  • Gregory Ing Liou
    Ophthalmology, Georgia Regents University, Augusta, GA
  • Norman Block
    Endocrine, Polypeptide & Cancer Institute, Veterans Affairs Medical Center, Miami, FL
  • Andrew Shally
    Endocrine, Polypeptide & Cancer Institute, Veterans Affairs Medical Center, Miami, FL
  • Manuela Bartoli
    Ophthalmology, Georgia Regents University, Augusta, GA
  • Footnotes
    Commercial Relationships Sean Shaw, None; Sagar Patel, None; Folami Lamoke, None; Jianghe Yuan, None; Alan Saul, None; Gregory Liou, None; Norman Block, None; Andrew Shally, None; Manuela Bartoli, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2179. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sean Shaw, Sagar Yatin Patel, Folami Lamoke, Jianghe Yuan, Alan Saul, Gregory Ing Liou, Norman Block, Andrew Shally, Manuela Bartoli; Protective effects of Growth Hormone Releasing Hormone (GHRH) agonism in the diabetic retina. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2179. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

The hypothalamic hormone GHRH has been shown to possess extrapituitary activities including neuroimmune and neuroprotective functions. We have previously shown that GHRH receptors are present in retinas of human and rodents and are mainly localized on retinal ganglion cells. Here we have explored the protective effects of the GHRH agonist JI-34 in the diabetic retina.

 
Methods
 

Streptozotocin-induced diabetic rats (STZ-rats) were kept diabetic for 6 weeks. One group of STZ-rats was also treated with 5μg/kg of the GHRH agonist JI-34 which was injected sub-cutaneously every other day starting one week after the induction of hyperglycemia and continued for the duration of diabetes. Immunohistochemical and Western analyses were conducted to assess the expression levels of GHRH-R, Intercellular adhesion molecule-1 (ICAM-1), Glial Fibrillary Acidic Protein (GFAP) and Vascular Endothelial Growth Factor (VEGF). Scotopic electroretinographic analysis was performed to assess neuroretinal function.

 
Results
 

Treatments of STZ-rats with JI-34 had no effect on blood glucose levels nor affected body weight changes with progression of diabetes. However, JI-34 treatments significantly reduced the expression levels of ICAM-1, GFAP and VEGF in the diabetic retina. In addition, we observed a strong up-regulation of GHRH-R expression in retinal ganglion cells of STZ-rats which resulted in a more evidenced neurofibrillary layer. These effects were associated with improved scotopic electroretinographic responses in STZ-rats treated with JI-34.

 
Conclusions
 

Our data show that the GHRH agonist JI-34 possesses protective effects in the diabetic retina by down-regulating inflammatory mediators and promoting neuroprotective responses probably involving preservation of ganglion cells activity and survival.

 
Keywords: 499 diabetic retinopathy • 615 neuroprotection  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×